• Je něco špatně v tomto záznamu ?

Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?

K. Malickova, Z. Kratka, S. Luxova, M. Bortlik, M. Lukas,

. 2020 ; 55 (8) : 917-919. [pub] 20200714

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20024861

Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has spread worldwide triggering a pandemic during the year 2020. The proportion of persons infected with SARS-CoV-2 whose infection remained subclinical is not known. However, such information is important to determine whether the control measures currently employed are sufficient to halt the spread of the virus. Current study has examined the seroprevalence of anti-SARS-CoV-2 antibodies in a population of 92 healthcare professionals working with patients with inflammatory bowel disease (IBD). The enzyme-linked immunosorbent assay (ELISA) test system for SARS-CoV-2 IgG from EUROIMMUN Medizinische Labordiagnostika AG (Germany) was used. Very low herd antibody-mediated immunity was proven, less than 2%, although we have been faced with the COVID-19 pandemic for several months. Anti-SARS-CoV-2 IgG antibody testing is currently unable to provide sufficient information about our anti-infectious immunity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024861
003      
CZ-PrNML
005      
20201222153555.0
007      
ta
008      
201125s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/00365521.2020.1791244 $2 doi
035    __
$a (PubMed)32663041
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Malickova, Karin $u Clinical and Research Center for Inflammatory Bowel Disease, ISCARE a.s, Prague, Czech Republic. Immunological Laboratory, GENNET, Prague, Czech Republic. Institute of Medical Biochemistry and Laboratory Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics? / $c K. Malickova, Z. Kratka, S. Luxova, M. Bortlik, M. Lukas,
520    9_
$a Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has spread worldwide triggering a pandemic during the year 2020. The proportion of persons infected with SARS-CoV-2 whose infection remained subclinical is not known. However, such information is important to determine whether the control measures currently employed are sufficient to halt the spread of the virus. Current study has examined the seroprevalence of anti-SARS-CoV-2 antibodies in a population of 92 healthcare professionals working with patients with inflammatory bowel disease (IBD). The enzyme-linked immunosorbent assay (ELISA) test system for SARS-CoV-2 IgG from EUROIMMUN Medizinische Labordiagnostika AG (Germany) was used. Very low herd antibody-mediated immunity was proven, less than 2%, although we have been faced with the COVID-19 pandemic for several months. Anti-SARS-CoV-2 IgG antibody testing is currently unable to provide sufficient information about our anti-infectious immunity.
650    _2
$a ambulantní zařízení $x organizace a řízení $7 D000554
650    _2
$a protilátky virové $x imunologie $7 D000914
650    _2
$a klinické laboratorní techniky $x metody $x statistika a číselné údaje $7 D019411
650    _2
$a koronavirové infekce $x diagnóza $x epidemiologie $x prevence a kontrola $7 D018352
650    _2
$a epidemický výskyt choroby $x prevence a kontrola $7 D004196
650    _2
$a ELISA $7 D004797
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdravotnický personál $7 D006282
650    _2
$a lidé $7 D006801
650    _2
$a kolektivní imunita $7 D032521
650    _2
$a imunoglobulin G $x analýza $x imunologie $7 D007074
650    _2
$a přenos infekce z pacienta na zdravotnického pracovníka $x prevence a kontrola $7 D017758
650    _2
$a idiopatické střevní záněty $x epidemiologie $x imunologie $x terapie $7 D015212
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a odhad potřeb $7 D020380
650    12
$a hygiena práce $7 D016272
650    _2
$a pandemie $x prevence a kontrola $x statistika a číselné údaje $7 D058873
650    _2
$a virová pneumonie $x epidemiologie $x prevence a kontrola $7 D011024
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a séroepidemiologické studie $7 D016036
651    _2
$a Německo $7 D005858
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kratka, Zuzana $u Immunological Laboratory, GENNET, Prague, Czech Republic.
700    1_
$a Luxova, Stepanka $u Immunological Laboratory, GENNET, Prague, Czech Republic.
700    1_
$a Bortlik, Martin $u Clinical and Research Center for Inflammatory Bowel Disease, ISCARE a.s, Prague, Czech Republic. Department of Internal Medicine, Military University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Lukas, Milan $u Clinical and Research Center for Inflammatory Bowel Disease, ISCARE a.s, Prague, Czech Republic. Institute of Medical Biochemistry and Laboratory Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
773    0_
$w MED00010598 $t Scandinavian journal of gastroenterology $x 1502-7708 $g Roč. 55, č. 8 (2020), s. 917-919
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32663041 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222153551 $b ABA008
999    __
$a ok $b bmc $g 1599006 $s 1115547
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 55 $c 8 $d 917-919 $e 20200714 $i 1502-7708 $m Scandinavian journal of gastroenterology $n Scand J Gastroenterol $x MED00010598
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace